The iPhone’s Shortcuts app is smarter than you think, you’re just using it wrong

The Shortcuts app has been around on iPhones for years. But thanks to native AI integration, it can now pull off multi-step, ...
Opinion

Picking the right security-risk compliance tool: A buyer’s framework, not hype

Selecting a compliance and risk platform is a high-stakes decision. The guidance below helps you focus on real capabilities—not marketing slogans—so you can choose a tool that fits your frameworks, ...

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation ...